Home > Newsletters > Drug Industry Daily > ANDAs Short on QbD Should Sit in 180-Day Review Queue, New OGD MAPP States
Drug Industry Daily
Oct. 5, 2012 | Vol. 11 No. 196
ANDAs Short on QbD Should Sit in 180-Day Review Queue, New OGD MAPP States
ANDAs that lack basic quality-by-design (QbD) elements will be categorized as requiring “major” amendments and more extensive FDA consideration, according to a new Manual of Policies and Procedures (MAPP) for reviewers in CDER’s Office of Generic Drugs (OGD).
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.